The Belgian Competition Authority confirms that Belgian merger control rules apply to the creation of loco-regional hospital networks pursuant to the Act of 28 February 2019

The Belgian Competition Authority confirms that Belgian merger control rules apply to the creation of loco-regional hospital networks pursuant to the Act of 28 February 2019
July 24, 2020

Following the recent legislative amendment obliging hospitals to establish and be part of a loco-regional hospital network,[1] the Belgian Competition Authority (‘BCA’) published on 22 July 2020 a note setting out the principles that will guide it when assessing the establishment of hospital networks and their possible qualification as a concentration under competition law.

Belgian competition law rules’ applicability to the establishment of loco-regional hospital networks

The BCA is competent to examine concentrations of a certain size in all sectors, which includes forms of collaboration between hospitals. Indeed, hospitals are undertakings within the meaning of competition law: they offer their services in return for remuneration, which is received either directly from patients or through their patients’ insurance. They are thus generally considered as engaging in an economic activity and therefore subject to competition laws.

The Act of 28 February 2019 states that health care facilities, including hospitals, must create and be part of a network of hospitals, whose tasks include: determining the strategy for the supply of loco-regional care assignments; and coordinating the supply of general and specialised care assignments between the loco-regional hospital network’s hospitals. In other words, hospitals are required to engage in a “network” that frames the collaboration between them. This network must have its own management, composed of both representatives of the individual hospitals as well as independent directors. The law provides that this management body can take decisions that bind the individual hospitals that are members of that local network.

In its note, the BCA has clearly indicated that competition rules on merger control apply in full to such loco-regional hospital network arrangements. This means that if the establishment of a hospital network fulfils the conditions of a notifiable concentration under the competition law rules enshrined in Book IV of the Belgian Code of Economic Law (‘CEL’), then it must be notified to and approved by the BCA before it is implemented.

Hospitals should be aware that the implementation of a concentration without the BCA’s prior approval could result in significant penalties. For example, the BCA may impose a fine of up to 10% of the annual turnover of the hospitals concerned if they implement a notifiable transaction before its clearance by the BCA.

Not every hospital network creation qualifies as a concentration

However, it should be noted that not all establishments of hospital networks automatically qualify as a concentration under competition law. To qualify as a concentration (that must or must not be notified to the BCA depending on the hospitals’ turnovers under Article IV.7 CEL), the hospital network concerned must bring about a lasting change in the individual hospitals’ control. As noted above, a network’s management body can take decisions that bind the individual hospitals that are members of that local network. Consequently, the decision structure of the network thus created and its influence on the strategic decisions of the individual hospitals are important criteria for determining whether such a change of control has occurred.

The question of whether a local regional network’s management body’s members have been given the power to take strategic decisions for the individual hospitals, which are part of the network, and has resulted in a lasting change of control (under competition law) over these hospitals has to be answered on a case-by-case basis and depends on the characteristics of each network. Account should be taken not only of the way in which these hospitals were controlled before the creation of the network, but also of the composition and decision-making rules of the managing body of the network to which they now belong.

To avoid delays in the setting up and implementation of the network, it is therefore of the utmost importance for hospitals to seek advice from the very beginning of the discussions or negotiations establishing such a hospital network to determine whether it would qualify as a concentration and needs prior clearance from the BCA. Hospitals must become aware of the potential competition law implications of the various structures they could envisage to set up their network and the obligations that they and the newly-created networks might have to comply with to avoid the fines that the BCA could impose if a notifiable concentration is implemented without the BCA’s prior approval.

Conclusion

Through its latest note, the BCA has again stressed that competition law rules concerning merger control fully apply to the creation of local hospital networks as required under the Act of 28 February 2019.

While the obligations under the merger control rules attached to such forms of cooperation between hospitals seem to be still little known to hospitals, the latter should be aware that more attention is given by the BCA to the sector and that the possible penalties for non-compliance with these merger control rules are significant.

Therefore, hospitals should seek solid legal advice either to verify whether the establishment of the hospital network qualifies as a concentration and whether that concentration must be notified, or to discuss the ways in which the network’s internal decision structure may possibly be organised to avoid a so-called lasting change of control and therefore the qualification as a concentration.

[1] Act of 28 February 2019 amending the coordinated Act of 10 July 2008 on hospitals and other health care institutions, concerning clinical networks between hospitals, the Belgian Official Gazette 28.03.2019.

Written by

  • Carmen Verdonck

    Partner

  • Nina Methens

    Associate

Recommended articles

November 24, 2022

Can parallel importers (re)brand generic medicines? The CJEU limits the ‘room for manoeuvre’

If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.

Read on
November 16, 2022

Invisible life to the rescue: European Commission facilitates approval of micro-organisms in plant protection products from 21 November 2022

Micro-organisms or microbes (e.g. bacteria, fungi or protozoa) are invisible to us but play a significant ecological role as they help to break down organic matter and produce oxygen. Some of them protect crops from pests and diseases, making them a suitable alternative to chemical-based plant protection. Given its ambition [...]

Read on
July 07, 2022

European Commission Unveils Measures to Unleash the Potential of Health Data

The European Commission has presented its Proposal for a Regulation on the European Health Data Space (the “Proposal”). While it aims to strengthen the rights of individuals and unlock data’s potential for research purposes, it also adds complexity to an already extensive legal framework.

Read on